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Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of motor neurons. Single-nucleotide
polymorphism rs3849942 is associated with ALS, tagging a hexanucleotide repeat mutation in the
C9orf72 gene. It is possible that there is more than 1 disease-causing genetic variation at this locus, in
which case association might remain after removal of cases carrying the mutation. DNA from patients
with ALS was therefore tested for the mutation. Genome-wide association testing was performed ﬁrst
using all samples, and then restricting the analysis to samples not carrying the mutation. rs3849942 and
rs903603 were strongly associated with ALS when all samples were included (rs3849942, p ¼ [3  2] 
106, rank 7/442,057; rs903603, p ¼ [7  6]  108, rank 2/442,057). Removal of the mutation-carrying
cases resulted in loss of association for rs3849942 (p ¼ [2  6]  103, rank 1225/442,068), but had little
effect on rs903603 (p ¼ [1  9]  105, rank 8/442,068). Those with a risk allele of rs903603 had an
excess of apparent homozygosity for wild type repeat alleles, consistent with polymerase chain reaction
failure of 1 allele because of massive repeat expansion. These results indicate residual association at the
C9orf72 locus suggesting a second disease-causing repeat mutation.
 2013 Elsevier Inc. All rights reserved.1. Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative
disease of motor neurons that causes relentless paralysis, with
death occurring within 2e5 years. The lifetime prevalence of ALS is
1 in 300 (Johnston et al., 2006) with peak onset at approximately
age 60 years, and an increased incidence in men (Chio et al., 2009).
Genetic studies of ALS have begun to yield insights, with 10
moderate to high penetrance Mendelian risk genes now identiﬁedl Neuroscience, Institute of
K. Tel.: þ44 20 7848 5187;
Chalabi).
ll rights reserved.for adult-onset ALS, with or without frontotemporal dementia
(FTD): SOD1 (Rosen et al., 1993), TARDBP (Gitcho et al., 2008;
Kabashi et al., 2008; Sreedharan et al., 2008), FUS (Kwiatkowski
et al., 2009; Vance et al., 2009), ANG (Greenway et al., 2006),
OPTN (Maruyama et al., 2010), VCP (Johnson et al., 2010), C9orf72
(DeJesus-Hernandez et al., 2011; Renton et al., 2011), FIG4 (Chow
et al., 2009), UBQLN2 (Deng et al., 2011), and PFN1 (Wu et al.,
2012). Other variations acting to increase risk might include inter-
mediate expansion of the ATXN2 gene (Elden et al., 2010), ELP3
intron 10 variation, a UNC13A single-nucleotide polymorphism
(SNP) (van Es et al., 2009), and indels in the NEFH tail domain
(Al-Chalabi et al., 1999; Figlewicz et al., 1994).
In approximately 5% of cases, a family history of ALS is recorded,
with the remaining cases labeled sporadic (Byrne and Hardiman,
A.R. Jones et al. / Neurobiology of Aging 34 (2013) 2234.e1e2234.e72234.e22010), but this distinction is artiﬁcial, with an increased risk of other
neurodegenerative diseases including Parkinson’s disease, and
frontotemporal dementia (Byrne and Hardiman, 2010; Millecamps
et al., 2010), and an increased risk of ALS in relatives of those
with apparently sporadic disease (Hanby et al., 2011). Furthermore,
variants in every Mendelian ALS gene have also been reported
in those with apparently sporadic ALS (Al-Chalabi and Lewis,
2011; van Blitterswijk et al., 2012), and the heritability of appar-
ently sporadic ALS has been estimated at 61% (Al-Chalabi et al.,
2010).
Genome-wide association studies in ALS and FTD recently
identiﬁed a locus on chromosome 9 within a known linkage peak
for ALS-FTD (Laaksovirta et al., 2010; Shatunov et al., 2010; van Es
et al., 2009). The disease-causing mutation has now been identi-
ﬁed as a massive expansion mutation of a hexanucleotide repeat
between noncoding exons 1A and 1B of C9orf72 (DeJesus-
Hernandez et al., 2011; Renton et al., 2011). Unaffected individuals
have 2e23 repeats of the (GGGGCC)n hexanucleotide microsatel-
lite, though the pathological repeat mutation might be several
hundred repeats. The mutation is interesting in manifesting with
at least 4 phenotypes: ALS, ALS-FTD, FTD, and normality.
Although 3 different genome-wide association studies all iden-
tiﬁed rs3849942 as the most associated SNP at the C9orf72 locus,
and it is clear that this is in strong linkage disequilibrium with the
repeat mutation (Smith et al., 2013), the UK subpopulation showed
stronger genome-wide signiﬁcant association at a different SNP,
rs903603. The most parsimonious explanation is that rs903603 and
rs3849942 are in strong linkage disequilibrium and both tag the
pathological expansion. If that is the case, one would expect that
removal of cases with the repeat mutation from the analysis would
obliterate the association at both SNPs. We therefore tested this
hypothesis in the UK population.
2. Methods
2.1. Sample collection
Whole blood samples from the Motor Neuron Disease (MND)
DNA Bank were used. Selection was based on no family history of
ALS, being of white European ancestry, and disease onset January
2002 or after. Control samples were obtained from the Depression
Case Control (DeCC) study, the Bipolar Affective Case Control Study
(BACCS), from Panos Deloukas of the Wellcome Trust Sanger
Institute (Cambridge, UK), and the British 1958 birth cohort DNA
collection. This project was ethically approved.
2.2. Sample preparation
DNA was extracted from blood samples by standard methods
within 1 week of bleeding and stored at the UK DNA Banking
Network in Manchester. Samples were bar-coded in a tracking
system to reduce risk of clerical error.
2.3. Genotyping
Genotyping and quality control was carried out as described
previously (Shatunov et al., 2010), but in brief, genome-wide
association was performed using various Illumina DNA micro-
arrays followed by standard quality control and association testing
using PLINK (Purcell et al., 2007).
The mutation was identiﬁed using repeat-primed polymerase
chain reaction (PCR) as described (DeJesus-Hernandez et al., 2011).
Nonmutation repeat length for alleles of the hexanucleotide repeat
was quantiﬁed using ampliﬁed fragment length polymorphism
(AFLP), using ﬂuorescently-labeled primers as detailed previously(DeJesus-Hernandez et al., 2011). Both analyses were performed
using an automated 3130XL capillary electrophoresis-based
Genetic Analyzer and GeneMapper v4.0 software (Applied
Biosystems).2.4. Statistical quality control
Statistical quality control excluded individuals with incongruent
sex, those marked for exclusion by the genotyping institution, those
with low genotyping per individual <0.02, those with phenotype
missingness <0.02, those with low heterozygosity (p < 0.05), those
exhibiting identity by descent sharing >5% of alleles with another
participant, and those not of white European ancestry.
Excluded SNP markers were those with a minor allele frequency
less than 0.015, SNP missingness <0.02, signiﬁcant departure from
Hardy-Weinberg equilibrium (p < 0.001), those marked for exclu-
sion by the genotyping institution, and those on chromosome X.2.5. Phasing and imputation analyses
Phasing and imputation was completed using 1000 Genomes
v2.20101123 autosomal release (http://www.1000genomes.org/),
performed using MaCH 1.0.18 (http://www.sph.umich.edu/csg/
abecasis/MACH/index.html) and minimac (http://genome.sph.
umich.edu/wiki/Minimac). We performed association analysis
on imputed data using ProbABEL (http://www.genabel.org/
packages/ProbABEL), mach2dat (http://genome.sph.umich.edu/
wiki/Mach2dat:_Association_with_MACH_output), and PLINK
v1.07 (http://pngu.mgh.harvard.edu/wpurcell/plink/index.shtml),
after creating input ﬁles using the GenGen (http://www.
openbioinformatics.org/gengen/) conversion tool. For GenGen,
we set the r2 threshold as 0.3 and, based on genotype posterior
probabilities derived in MaCH, a quality control threshold of 0.9.2.6. Association and haplotype analysis
To test for residual association and identify SNPs not related to
the mutation we used logistic regression, modeling case-control
comparisons with sex as a covariate, stratiﬁed by the presence or
absence of the repeat mutation.
We set the Bonferroni-corrected threshold of statistical signiﬁ-
cance at 1.13  107, and the genome-wide threshold as 5  108.
We used the R statistical package to construct Manhattan and
Q-Q Plots, LocusZoom (http://csg.sph.umich.edu/locuszoom/) for
regional Manhattan plots, and Haploview for haplotype block
maps (http://www.broadinstitute.org/scientiﬁc-community/science/
programs/medical-and-population-genetics/haploview/haploview).
To correct for genomic inﬂation, p values were adjusted by the
median c2 statistic (genomic control factor).
For linear regression analysis of the nonmutated microsatellite
repeat lengths as a quantitative variable we used PLINK v1.07 and
IBM SPSS 20. For haplotype analyses we used PLINK v1.07 sliding
windows between 2 and 100 to explore signiﬁcantly associated
haplotypes using the phased imputed dataset. The prevalence of
the most associated haplotypes were reﬁned in Haploview and
tested for their association with ALS using an omnibus haplotype
association analysis.
We ran all genetic tests under additive, dominant, and reces-
sive models, with little difference in results between dominant
and additive models. We have reported the additive model for
association of SNP alleles with the repeat mutation, and a domi-
nant model (using the larger allele) for the analysis of repeat
lengths.
Table 1
Change in rank by p value for residual and mutation-speciﬁc SNPs
SNP With hexanucleotide repeat
mutation
Without hexanucleotide repeat
mutation
Rank p Odds ratio
(allele)
Rank p Odds ratio
(allele)
rs10967976 First 6.16E-08 1.41 (G) 23rd 3.63E-05 1.31 (G)
rs903603 Second 7.55E-08 0.71 (A) Eighth 1.87E-05 0.76 (A)
rs10812611 Third 9.82E-08 1.4 (G) 34th 5.02E-05 1.3 (G)
rs3849942 Seventh 3.28E-06 1.39 (A) 1225th 2.57E-03 1.25 (A)
rs2814707 Ninth 5.00E-06 1.38 (A) 1562nd 3.30E-03 1.24 (A)
Key: SNP, single-nucleotide polymorphism.
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Four hundred eighty DNA samples of patients with sporadic ALS
were pooled in sets of 8. Each pool was tagged with 1 of 12 iden-
tifying DNA sequences and then combined into a further pool
containing 1 representative of each identifying sequence. Thus each
ﬁnal sample for sequencing contained the DNA of 96 different
individuals which could be resolved down to a group of 8. Samples
were sequenced using Illumina GAIIx platform generating 38-base
pair paired-end, indexed reads. Preliminary analysis and quality
control of reads was carried out using Illumina’s CASAVA v1.7
software and output ﬁles contained all ﬁltered, but unaligned,
sequences for each sample stored in a simple exportable FASTQ
format. Alignment of short reads against reference messengerRNA
sequence (uc003zqq.2, C9orf72, length ¼ 3233) and variations
calling was done using Maq 0.7.1 mapping short DNA sequencing
reads and calling variants using mapping quality scores with
default parameters (Li et al., 2008).
2.8. Sequencing the repeat
Forward (GGTTTAGGAGGTGTGTGTTTTTGT) and reverse primers
(CCAGCTTCGGTCAGAGAAAT) were designed to create a 424-base
pair amplicon (64% GC-rich) covering the repeat sequence. A
touchdown PCR protocol (see Supplementary Section S2) was used
to amplify the region of interest followed by gel electrophoresis to
inspect the amplicon length.
Samples were puriﬁed and analyzed using an ABI 3130xl Genetic
Analyzer (Applied Biosystems) with the BigDye Terminator v1.1
Cycle Sequencing Kit. ABI’s Sequencing Analysis 5.3.1 software was
used to analyze base calls and identify repeat patterns.
3. Results
3.1. C9orf72 genotyping
There were 632 case and 4519 control samples. After quality
control there were 599 case and 4136 control samples. There were
585,919 SNPs; after quality control 442,057. Thirty-nine cases tested
positive for the mutation; the remaining samples had repeat
lengths of less than 23 (Supplementary Section 1; Supplementary
Table 1).
3.2. Residual association
Genomic control factor lGC was 1.00e1.03 for all analyses.
Genome-wide association of all UK case versus control samples
conﬁrmed the ﬁndings of the original study (Shatunov et al., 2010),
with no newassociations (Supplementary Fig.1 and Supplementary
Table 2). The top 3 SNPs were rs10967976 (p ¼ 6.164  108; odds
ratio [OR], 1.41), rs903603 (p ¼ 7.548  108; OR, 0.71), and
rs10812611 (p ¼ 9.819  108; OR, 1.4), all at 9p21.2. Rs903603 was
the most associated SNP in the previous independent analysis
(Shatunov et al., 2010). In that study rs10967976 and rs10812611
had been removed for compatibility with the other platforms used
in the joint analysis. To conﬁrm that the observed association signal
was a result of the mutation and that there were no new associa-
tions, we performed association testing excluding the 39 mutation
positive cases (Supplementary Figs. 2 and 3, and Supplementary
Table 3). There was a residual association at 9p21 with the same
top 3 SNPs; rs903603 (p ¼ 1.87e-05; OR, 0.76), rs10967976 (p ¼
3.63e-05; OR, 1.31), and rs10812611 (p ¼ 5.02e-05; OR, 1.30), sug-
gesting that despite being at the disease locus, they are not tagging
the pathological repeat mutation. This is reﬂected in the change in p
value ranks with the most associated SNP from our original study,rs903603, remaining 1 of the 10most associated SNPs after removal
of cases with the mutation, compared with the SNP tagging the
repeat mutation, rs3849942, dropping from 7th to 1225th place, as
expected (Table 1).
We conﬁrmed that the mutation tagging SNP rs3849942 is
strongly associated with ALS when only samples positive for the
mutationwere tested against controls (p ¼ 9.77  1012; OR, 5.225;
rank ¼ 1), and rs903603 was not as strongly associated as
rs3849942 (p ¼ 7.73  107; OR, 0.24; rank ¼ 22) (Supplementary
Fig. 4). A Q-Q plot (Supplementary Fig. 5) did not show evidence
of inﬂation of the test statistic.
3.3. Residual association and mutation-speciﬁc haplotypes
To explore linkage disequilibrium in the region, we phased
and imputed SNPs at C9orf72 and the surrounding region
(chr9:27303051e27750375) using the 1000 Genomes Project
reference panel. Haplotype association analyses and reﬁnement of
haplotype blocks in Haploview identiﬁed a 79-SNP haplotype in
100% of the cases with the mutation (n ¼ 39), of which 72 SNPs
were from an 82-SNP haplotype published previously (Smith et al.,
2013). Using the same method we also identiﬁed a distinct 11-SNP
haplotype present in 76% of the samples without the mutation
(Supplementary Fig. 6).
3.4. Repeat length and risk allelic distribution
We examined the relationship between the hexanucleotide
repeat length of phased cases without the mutation (n ¼ 448) and
the allelic frequency and distribution of ALS-associated SNPs to
explore the linkage disequilibrium pattern of the locus. The
mutation-tagging SNP rs3849942 risk allele was associated with
increased hexanucleotide repeat numbers for the larger allele in
linear regression (b ¼ 5.711; p ¼ 3.02  1084) (Supplementary
Table 4). Allele frequency distributions of the repeat length strati-
ﬁed by rs3849942 alleles showed a marked difference between
thosewith 6 or less against 7 or more (Fig.1). Nonmutation samples
with 7 or more repeats (n ¼ 208) showed the strongest genome-
wide association with ALS when compared with control samples
(n ¼ 4142; OR, 4.99; p ¼ 1.35  1043) (Supplementary Table 5).
A similar relationship between risk alleles and hexanucleotide
repeat length was observed for the SNPs showing residual associ-
ation. Repeat numbers greater than 2 (the minimum length) for the
larger allele were signiﬁcantly associated with risk alleles at all of
the 3 SNPs showing residual association (Fig. 2). Modeling repeat
length as a quantitative variable in a linear regression conﬁrmed
that these SNPs were signiﬁcant predictors of having greater than 2
repeats (example SNP rs10812611; b ¼ 5.835; p ¼ 1.50  1052)
(Supplementary Table 4). Again, association testing of samples
with repeat length greater than 2 (n ¼ 385) against all controls
(n ¼ 4142) showed that SNPs showing residual association
Fig. 1. Relationship between rs3849942 alleles and repeat length in nonmutation
cases. The risk allele is strongly associated with longer repeat lengths, suggesting it
might lie on a haplotype promoting repeat length instability.
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p ¼ 2.21  1028; rs10812611: OR, 2.78; p ¼ 6.96  1033; and
rs10967976: OR, 2.82; p ¼ 1.19  1033 (Supplementary Table 6).
The identiﬁed 11-SNP haplotype for the residual association
SNPs was found in 100% of the samples with greater than 2 repeats
for larger allele (71% in control samples). Extension of the haplotype
to include an additional SNP, rs2492816, was very speciﬁc for longerA
B
C
Fig. 2. The relationship between hexanucleotide allele repeat length and single-
nucleotide polymorphisms (SNPs) showing residual association at the C9orf72 locus
SNP rs903603 (A), rs10967976 (B), and rs10812611 (C). Just as for the relationship for
rs3849942 shown in Fig. 1, the risk allele for SNPs on the alternative risk haplotype is
overwhelmingly likely to be associated with repeat sizes greater than 2.repeat lengths. This 12-SNP haplotype was strongly associated with
ALS in the sample set excluding cases with the mutation, or with 2
or less repeats (c2 ¼ 114; p ¼ 1.56  1024; Fig. 3). This haplotype
was not signiﬁcantly associated with ALS in cases with 2 hex-
anucleotide repeats and was not found at all in cases with the
pathological repeat mutation.
An omnibus association analysis comparing mutation-speciﬁc
and residual association haplotypes in those with the mutation
and those with greater than 2 repeats on their larger allele sup-
ported the hypothesis that the alleles showing residual association
at C9orf72 are signiﬁcantly associated with ALS, but not by associ-
ation with the pathological repeat mutation (Table 2).3.5. Apparent homozygosity for larger hexanucleotide repeats
associates with the risk allele of rs903603
The association of risk alleles with greater than 2 hexanucleotide
repeats suggests that residual association SNPs might predispose to
instability, and therefore a repeat mutation, as has been postulated
previously for the rs3849942 haplotypic background. Thus, 1
possible explanation of the residual association is an interrupted or
alternative repeat sequence, also pathologically expanded, but not
detected by repeat-primed PCR targeted at (GGGGCC)n (Fig. 4). In
that situation one would expect a similar problem to that reported
by DeJesus-Hernandez et al. (2011): that cases appear homozygous
because their larger repeat allele is too expanded to amplify. Most
cases (93.8%; 15/16 cases) with greater than 2 repeats and the
rs903603 risk allele were apparently homozygous for the hex-
anucleotide repeat allele, breaking HardyeWeinberg equilibrium.
In comparison, 66% (150/266) of cases with the same risk allele
were heterozygous for the repeat and we found only 4% (3/83) of
cases with the risk allele homozygous for 2 repeats (Table 3). We
did not observe this >2 repeat homozygosity bias for any other
SNPs. For example, 37% of cases with the mutation-speciﬁc risk
alleles had homozygosity for repeat alleles of length greater than 2,
which satisﬁed HardyeWeinberg equilibrium.3.6. Trimodal pattern of repeats
We found a trimodal pattern of repeat allele sizes, where the
occurrence of 2, 5, or 8 repeats was signiﬁcantly more frequent thanFig. 3. Twelve single-nucleotide polymorphism haplotypes for case samples with
repeat length greater than size 2.
Table 2
Association analyses of haplotypes with ALS in mutation and case samples with
hexanucleotide repeat length >2
Haplotype Haplotype p-value for association with ALS
Mutation-speciﬁc Residual
Mutation cases (n ¼ 39) 7.53 3 10L14 1.30 3 108
Cases with hexanucleotide
repeat length >2 (n ¼ 385)
9.87 3 109 5.91 3 10L23
Key: ALS, amyotrophic lateral sclerosis.
Values in bold highlight association between mutation groups and haplotypes.
Table 3
Frequency of cases by residual rs10967976 alleles stratiﬁed by repeat length and
zygosity
Repeat zygosity Nonrisk allele A (%) Risk allele G (%)
Heterozygous 76 (34) 150 (66)
Homozygous 2 repeats 80 (96) 3 (4)
Homozygous (repeats >2) 1 (5) 18 (95)
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suggest some repeat sizes are more stable than others.
3.7. Sequencing analysis of C9orf72
We identiﬁed 2 point mutations, a ketone G/T and an amine A/C
substitution, across 31 (n ¼ 272) and 2 (n ¼ 16) pools, respectively.
No group analyzed together or separately showed association with
the residual or mutation-speciﬁc risk haplotypes. There was also no
sample showing homozygosity for repeat sizes larger than 2. Thus it
is unlikely that the residual association identiﬁed is a result of the
observed point mutations.
3.8. Sequencing analysis of the C9orf72 repeat
We sequenced the repeat region in 56 samples: 18 cases
homozygous for greater than 2 repeats with the risk haplotype
showing residual association, 9 homozygous for repeats of size 2, 10
heterozygous for repeat length, and a mixture of non-ALS control
samples homozygous for repeat sizes greater than 2 (n ¼ 6),
homozygous for repeats of size 2 (n ¼ 7), and heterozygous for
repeat length (n ¼ 6). Our previous length and zygosity estimates
based on AFLP (Supplementary Fig. 9) and repeat-primed PCR were
correct for all these samples.
4. Discussion
We have shown that after removing cases with expansion
mutation of the (GGGGCC)n repeat at C9orf72 there remains
residual association of SNPs at this locus with ALS. As expected, the
SNPs associated with the mutation are no longer associated with
ALS in this sample, but rs903603 and SNPs in strong linkage
disequilibrium with it are associated, before and after the removal
of cases with the mutation. These SNPs showing residual associa-
tion reside on a distinct haplotype, different from that of the
mutation, and like the mutation-tagging SNPs, are also associated
with nonpathological expansion of the hexanucleotide repeat,
suggesting that they too promote instability of a repeat sequence.Fig. 4. Repeat-primed polymerase chain reaction results. Repeat-primed polymerase chain r
range (A), and a sample known to have a pathological (GGGGCC)n expansion mutation (B).Because the SNPs showing residual association are not associ-
ated with the mutation but are associated with ALS, repeat insta-
bility, and apparent homozygosity for the repeat, 1 possible
explanation is an alternative pathological expansion that is not
detected by repeat-primed PCR targeting (GGGGCC)n. Such an
alternative repeat sequence might be the result of an interrupted
repeat. Interrupted repeat sequences are found in ALS resulting
from intermediate expansion of a CAG trinucleotide repeat in the
ATXN2 gene, with CAA interrupting the sequence and resulting in
an alternative (Corrado et al., 2011). Interrupted sequences are also
found in Fragile X syndrome, a condition with a massive patho-
logical repeat expansion (Renciuk et al., 2009).
Others have reported evidence of pathological C9orf72 hex-
anucleotide expansions using Southern blot analysis without
corresponding detection of repeat-primed PCR in FTD cases,
consistent with an alternative repeat sequence (Pickering-Brown
et al., 2012).
Current evidence supports the idea that the sheer size of the
disease-associated C9orf72 hexanucleotide repeat expansion causes
pathology, with no evidence for repeat lengths below 23 being
associated with ALS. One would expect that an alternative repeat
that is also pathological should also be very large and not readily
ampliﬁed by PCR. In that case, samples carrying the alternative
repeat should appear homozygous for the nonexpanded allele
because the pathological allele would appear null using PCR.
Consistent with this, we ﬁnd cases with more than 2 repeats are
overwhelmingly likely to appear homozygous.
One factor increasing the likelihood of pathological expansion in
transmission to the next generation is the current size of the repeat,
and it is particularly interesting that the SNPs showing residual
association also strongly associated with alleles showing larger
numbers of nonpathological repeats. The C9orf72 region is very GC-
rich, known to increase vulnerability toward repeat mutations.
Additionally, a familial study examining inheritance of the repeat
mutation suggests that larger repeat lengths are indeed more
unstable and prone to expansion (Beck et al., 2013).
We found a trimodal pattern of repeat allele sizes with signiﬁ-
cant departure from a uniform distribution for repeat lengths
2, 5, and 8. This pattern is also apparent in previous publications
(DeJesus-Hernandez et al., 2011; Smith et al., 2013), although not
explicitly described. The tendency to increase the allele size byeaction of example case samples showing a small expansion in the nonpathological size
A.R. Jones et al. / Neurobiology of Aging 34 (2013) 2234.e1e2234.e72234.e618 nucleotides might be related to the underlying pathological
mechanism of expansion, either because the mechanism results in
preferential expansion in units of 18 base pairs, or because ex-
pansion in other unit sizes is unstable and leads to massive path-
ological expansion.
A weakness of this study is that we relied on repeat-primed
PCR to identify cases with the mutation. It is possible that some
cases with the mutation were missed and this explains the
residual association. Several factors make this unlikely. First, the
mutation is tagged by rs3849942, and as expected, this SNP lost
association with ALS after the removal of mutation-positive
cases, and rs903603 remained in the top 10 associated SNPs.
Second, the frequency of identiﬁed mutation cases in our sample
is among the highest in the world (Smith et al., 2013), suggesting
we are not missing a large proportion of these. Third, we per-
formed a standard PCR of the hexanucleotide repeat and assayed
the length polymorphism of the alleles (AFLP); in all cases, there
were no heterozygous cases with the expansion, suggesting that
the detection method worked. Fourth, in all cases in which
sequence data were available, the repeat size on sequencing
matched our estimate of size based on AFLP and repeat-primed
PCR.
Another explanation for our ﬁndings is a substitution or similar
mutation, rather than an alternative repeat mutation. This seems
unlikely because for several years many groups, including ours,
performed sequencing through the region ﬁnding no segregating
point mutations or indels. Furthermore, the point mutations we
identiﬁed on sequencing do not occur in individuals carrying the
alternative risk haplotype. It does however remain possible that for
a small subset of individuals with sporadic ALS, point mutations of
C9orf72 are pathogenic, but it is then difﬁcult to explain the asso-
ciation between rs903603 risk alleles and hexanucleotide repeats
greater than a length of 2. Nevertheless, we cannot exclude this
possibility.
A third possibility is that SNPs showing residual association tag
repeat alleles greater than size 2 because such repeats are them-
selves pathogenic. Case and control samples share the same
frequency and distribution of repeat lengths (Rutherford et al.,
2012) making this unlikely, but recent evidence suggests that
moderate expansion in the number of repeats can actually be
pathogenic (Gomez-Tortosa et al., 2013).
We present evidence of residual association at the C9orf72 locus
in ALS, not accounted for by the known pathological GGGGCC
hexanucleotide repeat expansion but consistent with the hypoth-
esis of an interrupted GGGGCC or alternative sequence repeat. We
present a new pathological haplotype associated with ALS at this
locus that is associated with having greater than 2 repeats for the
larger allele, suggesting this haplotype predisposes to repeat
instability. Further investigation including Southern blot analysis of
individuals carrying the risk haplotype and sequence analysis of the
region will help to identify the cause of the residual association
signal we have identiﬁed.Disclosure statement
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